ANGO AngioDynamics Inc

Fiscal 2019 Third Quarter Highlights

• Net sales of $86.3 million, an increase of 3.0% year over year
• Gross margin declined 10 basis points year over year to 54.1%
• GAAP EPS of $0.02 per share; adjusted EPS of $0.19 per share
• Cash provided by operations of $8.3 million; capital expenditures of $0.9 million
• Received unconditional IDE approval from the FDA to initiate NanoKnife® DIRECT Clinical Study
• Won patent infringement dispute with Bard

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the third quarter of fiscal year 2019, which ended February 28, 2019.

“While we had pockets of softness in our financial performance during the third quarter, our overall performance remains strong, and we are confident that we will achieve our full-year guidance. We saw strong growth contributions during the quarter from AngioVac and Solero, as well as from Fluid Management,” commented Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. “Additionally, I am very excited that the FDA has approved the IDE for our NanoKnife® DIRECT Clinical Study, which is the next step toward this incredible technology improving the standard of care for patients afflicted with Stage III pancreatic cancer. The IDE approval also represents a milestone for AngioDynamics as we transform into an evidence-based Company focused on therapies and outcomes facilitated by our unique technologies.”

Third Quarter 2019 Financial Results

Net sales for the third quarter of fiscal 2019 were $86.3 million, an increase of 3.0%, compared to $83.9 million a year ago. Foreign currency translation did not have a significant impact on the Company’s sales in the quarter.

• Oncology net sales were $13.9 million, an increase of 15.1% from $12.1 million a year ago, as strong sales of Solero, as well as the recent BioSentry and RadiaDyne acquisitions, more than offset weaker than anticipated NanoKnife capital sales during the quarter.
• Vascular Interventions and Therapies net sales in the third quarter of fiscal 2019 were $50.1 million, an increase of 3.3%, compared to $48.5 million a year ago, as strong growth in AngioVac was partially offset by a decelerating decline in the Venous Insufficiency business.
• Vascular Access net sales were $22.3 million, a decrease of 4.0% from $23.3 million a year ago, as lower sales of midlines, PICCs, and ports were somewhat offset by strong dialysis sales.

U.S. net sales in the third quarter of fiscal 2019 were $68.3 million, an increase of 3.9% from $65.8 million a year ago, and International net sales were $18.0 million, a decrease of 0.3% from $18.1 million a year ago.

Gross margin for the third quarter of fiscal 2019 declined 10 basis points to 54.1% from 54.2% a year ago. This reflects temporary headwinds related to FX and a one-time positive impact from plant closures recognized last year. The Company continues to see gains in gross margin related to operational and supply-chain improvements.

The Company recorded net income of $0.8 million, or $0.02 per share, in the third quarter of fiscal 2019. This compares to net income of approximately $14.0 million, or $0.37 per share, a year ago.

Excluding the items shown in the non-GAAP reconciliation table below, adjusted net income for the third quarter of fiscal 2019 was $7.4 million, or $0.19 per share, compared to adjusted net income of $8.7 million, or $0.23 per share, in the third quarter of fiscal 2018.

Adjusted EBITDAS in the third quarter of fiscal 2019, excluding the items shown in the reconciliation table below, was $14.9 million, compared to $16.8 million in the third quarter of fiscal 2018.

In the third quarter of fiscal 2019, the Company generated $8.3 million in operating cash flow and had capital expenditures of $0.9 million. As of February 28, 2019, the Company had $41.7 million in cash and cash equivalents and $133.8 million in debt, excluding the impact of deferred financing costs.

Nine Months Financial Results

For the nine months ended February 28, 2019:

• Net sales were $263.2 million, an increase of 2.8%, compared to $256.0 million for the same period a year ago.
• The Company's net income was $2.5 million, or $0.06 per share, compared to net income of $14.2 million, or $0.38 per share, a year ago.
• Gross margin improved 270 basis points to 53.3% from 50.6% a year ago.
• Excluding the items shown in the non-GAAP reconciliation table below, adjusted net income was $22.0 million, or $0.57 per share, compared to adjusted net income of $19.9 million, or $0.53 per share, a year ago.
• Adjusted EBITDAS, excluding the items shown in the reconciliation table below, was $43.9 million, compared to $41.5 million for the same period a year ago.

Fiscal Year 2019 Financial Guidance

The Company reiterates its previously announced financial guidance, continuing to expect fiscal year 2019 net sales in the range of $354 to $359 million and free cash flow in the range of $26 to $31 million. Additionally, the Company continues to expect adjusted earnings per share in the range of $0.82 to $0.86.

Conference Call

The Company’s management will host a conference call today at 8:00 a.m. ET to discuss its third quarter 2019 results.

To participate in the conference call, dial 1-877-407-0784 (domestic) or 1-201-689-8560 (international) and refer to the passcode 13688664.

This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available from 11:00 a.m. ET on Tuesday, April 2, 2019, until 11:59 p.m. ET on Tuesday, April 9, 2019. To hear this recording, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and enter the passcode 13688664.

Use of Non-GAAP Measures

Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release, AngioDynamics has reported adjusted EBITDAS, adjusted net income, adjusted earnings per share and free cash flow. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

About AngioDynamics, Inc.

AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products. For more information, visit www.angiodynamics.com.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of fourth parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, challenges with respect to fourth-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2018. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue and is similarly approved for commercialization in Canada, the European Union, and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.

          ANGIODYNAMICS, INC. AND SUBSIDIARIES CONSOLIDATED INCOME STATEMENTS

(in thousands, except per share data)

  Three months ended Nine months ended February 28,     February 28, February 28,     February 28, 2019 2018 2019 2018 (unaudited) (unaudited)   Net sales $ 86,341 $ 83,851 $ 263,184 $ 255,968 Cost of sales (exclusive of intangible amortization) 39,650   38,403   122,917   126,560   Gross profit 46,691   45,448   140,267   129,408   % of net sales 54.1 % 54.2 % 53.3 % 50.6 %   Operating expenses Research and development 7,210 6,457 22,235 19,005 Sales and marketing 19,413 18,009 59,115 56,378 General and administrative 8,780 7,723 26,612 23,319 Amortization of intangibles 5,342 4,191 14,646 12,433 Change in fair value of contingent consideration 609 31 865 218 Acquisition, restructuring and other items, net 2,550   4,177   9,700   11,932   Total operating expenses 43,904   40,588   133,173   123,285   Operating income 2,787 4,860 7,094 6,123 Interest expense, net (1,442 ) (740 ) (3,689 ) (2,223 ) Other income (expense), net (266 ) (49 ) (72 ) 238   Total other expense, net (1,708 ) (789 ) (3,761 ) (1,985 ) Income before income taxes 1,079 4,071 3,333 4,138 Income tax expense (benefit) 283   (9,948 ) 866   (10,095 ) Net Income $ 796   $ 14,019   $ 2,467   $ 14,233     Earnings per share Basic $ 0.02 $ 0.38 $ 0.07 $ 0.38 Diluted $ 0.02 $ 0.37 $ 0.06 $ 0.38   Weighted average shares outstanding Basic 37,518 37,122 37,446 37,031 Diluted 38,338 37,442 38,350 37,358     ANGIODYNAMICS, INC. AND SUBSIDIARIES GAAP TO NON-GAAP RECONCILIATION

(in thousands, except per share data)

  Reconciliation of Net Income to non-GAAP Adjusted Net Income:                   Three months ended Nine months ended February 28, February 28, February 28, February 28, 2019 2018 2019 2018 (unaudited) (unaudited)   Net Income $ 796 $ 14,019 $ 2,467 $ 14,233   Amortization of intangibles 5,342 4,191 14,646 12,433 Change in fair value of contingent consideration 609 31 865 218 Acquisition, restructuring and other items, net (1) 2,550 4,177 9,700 11,932 Tax effect of non-GAAP items (2) (1,920 ) (13,766 ) (5,699 ) (18,889 ) Adjusted net income $ 7,377   $ 8,652   $ 21,979   $ 19,927     Reconciliation of Diluted Earnings Per Share to non-GAAP Adjusted Diluted Earnings Per Share:   Three months ended Nine months ended February 28, February 28, February 28, February 28, 2019 2018 2019 2018 (unaudited) (unaudited)   Diluted earnings per share $ 0.02 $ 0.37 $ 0.06 $ 0.38   Amortization of intangibles 0.14 0.11 0.38 0.33 Change in fair value of contingent consideration 0.02 0.00 0.02 0.01 Acquisition, restructuring and other items, net (1) 0.07 0.11 0.25 0.32 Tax effect of non-GAAP items (2) (0.06 ) (0.36 ) (0.14 ) (0.51 ) Adjusted diluted earnings per share $ 0.19   $ 0.23   $ 0.57   $ 0.53     Adjusted diluted sharecount 38,338 37,442 38,350 37,358   (1) Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(2) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company’s U.S. deferred tax assets and an effective tax rate of 23% for February 28, 2019. For February 28, 2018, the effective tax rate i) has been calculated using a blended rate of 30.62% for the year ended May 31, 2018 due to the enactment of the Tax Cuts and Jobs Act (the “Act”) that reduced the federal corporate tax rate to 21%; ii) excludes the benefit recorded in Q3 fiscal 2018 resulting from remeasurement of the Company’s deferred tax assets from the Act; iii) tax effects the non-GAAP adjustment shown above and iv) assumes the Company does not have a valuation allowance on its U.S. deferred tax assets.

    ANGIODYNAMICS, INC. AND SUBSIDIARIES GAAP TO NON-GAAP RECONCILIATION (Continued)

(in thousands, except per share data)

  Reconciliation of Net Income to EBITDAS and Adjusted EBITDAS:                   Three months ended Nine months ended February 28, February 28, February 28, February 28, 2019 2018 2019 2018 (unaudited) (unaudited)   Net Income $ 796 $ 14,019 $ 2,467 $ 14,233   Income tax expense (benefit) 283 (9,948 ) 866 (10,095 ) Interest expense, net 1,442 740 3,689 2,223 Depreciation and amortization 6,867 5,718 19,158 17,395 Stock based compensation 2,378   2,058   7,119   5,821   EBITDAS $ 11,766   $ 12,587   $ 33,299   $ 29,577     Change in fair value of contingent consideration $ 609 $ 31 $ 865 $ 218 Acquisition, restructuring and other items, net (1) 2,550   4,216   9,700   11,656   Adjusted EBITDAS $ 14,925   $ 16,834   $ 43,864   $ 41,451     Per diluted share: EBITDAS $ 0.31 $ 0.34 $ 0.87 $ 0.79 Adjusted EBITDAS $ 0.39 $ 0.45 $ 1.14 $ 1.11   (1) Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items.             ANGIODYNAMICS, INC. AND SUBSIDIARIES NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY

(in thousands)

  Three months ended Nine months ended

Feb 28,2019

   

Feb 28,2018

   

%Growth

   

CurrencyImpact

   

ConstantCurrencyGrowth

Feb 28,2019

   

Feb 28,2018

   

%Growth

   

CurrencyImpact

   

ConstantCurrencyGrowth

  Net Sales by Product Category Vascular Interventions & Therapies $ 50,115 $ 48,517 3.3% $ 152,603 $ 149,751 1.9% Vascular Access 22,348 23,279 (4.0)% 69,861 69,091 1.1% Oncology 13,878   12,055   15.1% 40,720   37,126   9.7% Total $ 86,341   $ 83,851   3.0% 0.0% 3.4% $ 263,184   $ 255,968   2.8% 0.0% 3.1%

 

 

  Net Sales by Geography United States $ 68,331 $ 65,787 3.9% 0.0% 3.9% $ 207,898 $ 203,020 2.4% 0.0% 2.4% International 18,010   18,064   (0.3)% 2.0% 1.9% 55,286   52,948   4.4% 2.0% 5.6% Total $ 86,341   $ 83,851   3.0% 0.0% 3.4% $ 263,184   $ 255,968   2.8% 0.0% 3.1%             ANGIODYNAMICS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS

(in thousands)

  February 28, 2019 May 31, 2018 (unaudited) (audited) Assets Current assets: Cash and cash equivalents $ 41,704 $ 74,096 Marketable securities —   1,317 Total cash and investments 41,704 75,413   Accounts receivable, net 44,208 39,401 Inventories 52,388 48,916 Prepaid expenses and other 4,440   4,302 Total current assets 142,740 168,032   Property, plant and equipment, net 41,207 42,461 Other assets 3,610 3,417 Intangible assets, net 166,564 130,310 Goodwill 423,674   361,252 Total assets $ 777,795   $ 705,472 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 18,443 $ 15,775 Accrued liabilities 21,929 34,426 Current portion of long-term debt 6,250 5,000 Current portion of contingent consideration 6,673   2,100 Total current liabilities 53,295 57,301   Long-term debt, net of current portion 126,837 86,621 Deferred income taxes 17,834 17,173 Contingent consideration, net of current portion 20,454 1,161 Other long-term liabilities 5,296   621 Total liabilities 223,716 162,877   Stockholders' equity 554,079   542,595 Total Liabilities and Stockholders' Equity $ 777,795   $ 705,472             ANGIODYNAMICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

  Three months ended Nine months ended February 28,     February 28, February 28,     February 28, 2019 2018 2019 2018 (unaudited) (unaudited) Cash flows from operating activities: Net Income $ 796 $ 14,019 $ 2,467 $ 14,233 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 6,867 5,718 19,158 17,395 Stock based compensation 2,378 2,058 7,119 5,821 Change in fair value of contingent consideration 609 31 865 218 Deferred income taxes 138 (10,044 ) 633 (10,150 ) Change in accounts receivable allowances (24 ) (315 ) (99 ) (35 ) Fixed and intangible asset impairments and disposals 677 22 689 30 Other 12 (78 ) (5 ) (635 ) Changes in operating assets and liabilities, net of acquisitions: Accounts receivable (785 ) 598 (3,853 ) 2,897 Inventories (1,747 ) (2,511 ) (2,702 ) (1,913 ) Prepaid expenses and other (325 ) 155 (1,508 ) (548 ) Accounts payable, accrued and other liabilities (254 ) (5,338 ) (10,336 ) (9,797 ) Net cash provided by operating activities 8,342   4,315   12,428   17,516   Cash flows from investing activities: Additions to property, plant and equipment (887 ) (425 ) (2,303 ) (1,647 ) Acquisition of intangibles — (1,265 ) — (1,265 ) Cash paid in acquisition — — (84,920 ) — Proceeds from sale of marketable securities 1,350   —   1,350   —   Net cash used in investing activities 463   (1,690 ) (85,873 ) (2,912 ) Cash flows from financing activities: Proceeds from issuance of long-term debt — — 55,000 — Repayment of long-term debt (11,250 ) (1,250 ) (13,750 ) (3,750 ) Payment of contingent consideration previously established in purchase accounting — — (2,100 ) (9,500 ) Proceeds from exercise of stock options and employee stock purchase plan 1,169   822   2,023   2,560   Net cash provided by (used) in financing activities (10,081 ) (428 ) 41,173   (10,690 ) Effect of exchange rate changes on cash and cash equivalents 160   239   (120 ) 834   Increase (decrease) in cash and cash equivalents (1,116 ) 2,436 (32,392 ) 4,748 Cash and cash equivalents at beginning of period 42,820   49,856   74,096   47,544   Cash and cash equivalents at end of period $ 41,704   $ 52,292   $ 41,704   $ 52,292             ANGIODYNAMICS, INC. AND SUBSIDIARIES GAAP TO NON-GAAP RECONCILIATION

(in thousands)

  Reconciliation of Free Cash Flows:       Three months ended Nine months ended February 28,     February 28, February 28, February 28, 2019 2018 2019 2018 (unaudited) (unaudited)   Net cash provided by operating activities $ 8,342 $ 4,315 $ 12,428 $ 17,516 Additions to property, plant and equipment (887 ) (425 ) (2,303 ) (1,647 ) Free Cash Flow $ 7,455   $ 3,890   $ 10,125   $ 15,869    

View source version on businesswire.com: https://www.businesswire.com/news/home/20190402005340/en/

Investors:AngioDynamics, Inc.Michael C. Greiner, Executive Vice President & CFO(518) 795-1821